**UNITED STATES PATENT AND TRADEMARK OFFICE**

Re: Application of: Ronald M. BURCH, et al.  
Serial No.: 10/056,348  
Filed: January 25, 2002  
Examiner: Bennett M. Celsa  
For: **ANALGESIC COMBINATION OF  
OXYCODONE AND NABUMETONE**

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA, 22313-1450

November 4, 2004

Sir:

In accordance with Applicant's duty of disclosure under 37 C.F.R. §1.56 and the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby make of record the single document listed on the accompanying Form PTO-1449 for consideration by the Examiner in connection with the examination of the above-identified patent application.


The document reports the assessment of the effects of combined administration of oxycodone with either of celecoxib, etodolac or rofecoxib, as performed by Purdue Pharma L.P., which is associated with the assignee of the present invention.

This Information Disclosure Statement is being filed after a First Office Action but before a Final Office Action or Notice of Allowance. Pursuant to 37 C.F.R. § 1.98(c), a check for \$180.00 is enclosed to cover the required fee. However, if it is determined that any fee is due, the Examiner is authorized to charge said fee to Attorney Deposit Account No. 50-0552.

It is respectfully requested that the reference cited on the accompanying Form PTO-1449  
be considered and made of record.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By   
Robert J. Paradiso  
Reg. No. 41,240

Davidson, Davidson & Kappel, LLC  
485 Seventh Avenue, 14<sup>th</sup> Floor  
New York, New York 10018  
(212) 736-1940



**UNITED STATES PATENT AND TRADEMARK OFFICE**

Re: Application of: Ronald M. BURCH, et al.  
Serial No.: 10/056,348  
Filed: January 25, 2002  
Examiner: Bennett M. Celsa  
For: **ANALGESIC COMBINATION OF  
OXYCODONE AND NABUMETONE**

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA, 22313-1450

November 4, 2004

Sir:


In accordance with Applicant's duty of disclosure under 37 C.F.R. §1.56 and the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby make of record the references listed on the accompanying Form PTO-1449 (1 page) for consideration by the Examiner in connection with the examination of the above-identified patent application. In accordance with 37 C.F.R. § 1.98 (a), copies of the listed references are enclosed.

The present Information Disclosure Statement is filed under 37 C.F.R. §1.97(b), after the mailing of a first Office Action on the merits. Accordingly, a fee of \$ 180.00 is enclosed. However, if it is determined that there is a deficiency or an overpayment, the Examiner is authorized to charge said deficiency or credit said overpayment to Attorney Deposit Account No. 50-0552.

It is respectfully requested that the reference cited on the accompanying Form PTO-1449  
be considered and made of record.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By 

Robert J. Paradiso  
Reg. No. 41,240

Davidson, Davidson & Kappel, LLC  
485 Seventh Avenue, 14<sup>th</sup> Floor  
New York, New York 10018  
(212) 736-1940

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON4		SERIAL NO.: 10/056,348	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Ronald BURCH et al.			
				FILING DATE: January 25, 2002		GROUP: 1639	

U.S. PATENT DOCUMENTS												
*EXAMINER INITIAL	AA	AB	AC	AD	AE	AF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS									
AG	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
						Yes	No		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)		
AH	Tanaka et al., "Pharmacological Studies of the New Antiinflammatory Agent 3-Formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one," <i>Arzneim-Forsch./Drug res.</i> 42 (II), Nr. 7, pp. 935-944 (1992)	
AI	Engelhardt et al., "Anti-inflammatory, Analgesic, Antipyretic and Related Properties of Meloxicam, a New Non-steroidal Anti-inflammatory Agent with Favorable Gastrointestinal Tolerance," <i>Inflamm. Res.</i> 44:423-433 (1995)	
AJ	Engelhardt, "Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2," <i>Brit. J. Rheumatology</i> 1996:35 (suppl. 1): 4-12	
AK	Distel et al., "Safety of Meloxicam: A Global Analysis of Clinical Trials," <i>Brit. J. Rheumatology</i> 1996:35 (suppl. 1):68-77	
AL	Wojtulewski et al., "a Six Month Double-blind Trial to Compare the Efficacy and Safety of Meloxicam 7.5 mg Daily and Naproxen 750 mg Daily in Patients with Rheumatoid Arthritis," <i>Brit. J. Rheumatology</i> 1996:35 (suppl. 1):22-28	
AM	Swingle et al., "Preclinical Pharmacological Studies With Nimesulide," <i>Drugs Exptl. Clin. Res. Vol. X</i> (8-9) pp. 587-597	
AN	Rabasseda, "Nimesulide: A Selective Cyclooxygenase 2 inhibitor Antiinflammatory Drug," <i>Drugs of Today</i> Vol 32, No.5 (1996), p9. 365-384	
AO	Siebert et al., "Pharmacological and Biochemical Demonstration of the Role of Cyclooxygenase 2 in Inflammation and Pain," <i>PNAS USA</i> Vol.91 (Dec. 1994) pages 12013-12-17	
AP	Richardson et al., "The Clinical Implications of Inhibition of the Inducible Form of Cyclo-oxygenase," <i>Drug Safety</i> Vol. 15(4), pp. 249-260 (Oct. 1996)	
AQ		

EXAMINER		DATE CONSIDERED
----------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.